Company Thermo Fisher Scientific, Inc.
Equities
TMO
US8835561023
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 542.83 USD | +0.09% |
|
-6.18% | -6.32% |
| Feb. 05 | Microsoft-Backed OpenAI Launches Frontier Platform to Manage Enterprise AI Agents | MT |
| Feb. 05 | IQVIA forecasts weak annual profit on higher interest expenses | RE |
Business description: Thermo Fisher Scientific, Inc.
- laboratory equipments (73.2%). Moreover, the group proposes chemical products (reagents, solvent, salts, etc.), consumable products (tubes, funnels, vials, etc.), as well as conditioning, warehousing, storage, etc.;
- scientific analysis equipments (16.7%): analyzer (of water, gas, grounds, etc.), mass spectrometers, molecular spectroscopes, microscopes, manometers, samplers, microbiology equipments, reactive agents, etc.;
- diagnostics equipment and products (10.1%).
Net sales break down by source of revenue between sales of products (58.4%) and services (41.6%).
Net sales break down geographically as follows: North America (52.5%), Europe (25.3%), Asia/Pacific (18.6%) and other (3.6%).
Number of employees: 125,000
Sales by Activity: Thermo Fisher Scientific, Inc.
| Fiscal Period: December | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) |
|---|---|---|---|---|---|
Laboratory Products and Biopharma Services | 12.24B | 14.86B | 22.51B | 23.04B | 23.16B |
Analytical Instruments | 5.12B | 6.07B | 6.62B | 7.26B | 7.46B |
Life Sciences Solutions | 12.17B | 15.63B | 13.53B | 9.98B | 9.63B |
Specialty Diagnostics | 5.34B | 5.66B | 4.76B | 4.4B | 4.51B |
Eliminations | -2.66B | -3.01B | -2.52B | -1.83B | -1.88B |
Geographical breakdown of sales: Thermo Fisher Scientific, Inc.
| Fiscal Period: December | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) |
|---|---|---|---|---|---|
United States | 16.44B | 18.91B | 23.82B | 22.01B | 21.76B |
Other Regions | 12.99B | 16.86B | 17.3B | 20.84B | 21.12B |
China | 2.8B | 3.44B | 3.79B | - | - |
Executive Committee: Thermo Fisher Scientific, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Marc Casper
CEO | Chief Executive Officer | 58 | 2009-10-14 |
| Director of Finance/CFO | 59 | 2015-07-31 | |
Sebastian Pacios
CTO | Chief Tech/Sci/R&D Officer | - | 2023-09-30 |
Ryan Snyder
CTO | Chief Tech/Sci/R&D Officer | - | 2018-12-31 |
Karen Nelson
CTO | Chief Tech/Sci/R&D Officer | - | 2021-06-30 |
Composition of the Board of Directors: Thermo Fisher Scientific, Inc.
| Director | Title | Age | Since |
|---|---|---|---|
Scott Sperling
BRD | Director/Board Member | 68 | 2006-11-08 |
Marc Casper
CHM | Chairman | 58 | 2020-02-25 |
Tyler Jacks
BRD | Director/Board Member | 65 | 2009-05-25 |
Nelson Chai
BRD | Director/Board Member | 60 | 2010-12-09 |
C. Harris
BRD | Director/Board Member | 69 | 2012-03-29 |
Dion Weisler
BRD | Director/Board Member | 58 | 2017-02-28 |
James Mullen
BRD | Director/Board Member | 67 | 2018-11-06 |
Debora Spar
BRD | Director/Board Member | 62 | 2019-09-04 |
R. Keith
BRD | Director/Board Member | 58 | 2020-11-19 |
Ruby Chandy
BRD | Director/Board Member | 64 | 2022-02-28 |
Company details: Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
168 Third Avenue
02451, Waltham
+781 622 1000
http://www.thermofisher.com
Group companies: Thermo Fisher Scientific, Inc.
| Name | Category and Sector |
|---|---|
PharmaFluidics NV
PharmaFluidics NV Develops micro chip liquid chromatography cartridges for analysis of complex biological samples | |
Acros Organics BV
Acros Organics BV Wholesale DistributorsDistribution Services Distributes organic chemicals |
Wholesale Distributors
|
Thermo Fisher Scientific India Pvt Ltd.
Thermo Fisher Scientific India Pvt Ltd. Manufactures pharmaceutical products | |
Thermo Fisher Scientific India Pvt Ltd.
Thermo Fisher Scientific India Pvt Ltd. Manufactures pharmaceutical products | |
PPD Pharmaceutical Development India Pvt Ltd. |
Other Advanced Medical Equipment & Technology
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.09% | -6.18% | -5.22% | -5.79% | 204B | ||
| +2.48% | -3.19% | -17.05% | +96.06% | 173B | ||
| +0.40% | -1.04% | +3.14% | -17.87% | 153B | ||
| -1.76% | -18.45% | -27.38% | +60.03% | 113B | ||
| -2.82% | -1.83% | -27.55% | -21.47% | 54.57B | ||
| +0.78% | -3.26% | +10.87% | -0.48% | 45.68B | ||
| +1.72% | +5.16% | +14.52% | +22.65% | 39.57B | ||
| -2.02% | +2.13% | -8.92% | +12.23% | 36.76B | ||
| -0.05% | -3.19% | -12.23% | -14.88% | 36.65B | ||
| -1.36% | +0.12% | -21.05% | -40.13% | 33.03B | ||
| Average | -0.39% | -3.20% | -9.08% | +9.04% | 88.98B | |
| Weighted average by Cap. | -0.11% | -5.27% | -9.60% | +20.01% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.

Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- TMO Stock
- Company Thermo Fisher Scientific, Inc.
Select your edition
All financial news and data tailored to specific country editions

















